TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Comparison of Conventional Adult Out-of-hospital Cardiopulmonary Resuscitation Against a Concept With Mechanical Chest Compressions and Simultaneous Defibrillation
Brief Summary: The primary objective is to show superiority in survival of the modified method with the LUCAS Chest Compression System, compared to the conventional manual resuscitation method in patients suffering from out of hospital sudden cardiac arrest.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Impedance Threshold Device (ITD) | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: Sham ITD | Arm Label: 3; Type: OTHER; Interventions: Other: Analyze early | Arm Label: 4; Type: OTHER; Interventions: Other: Analyze later | Intervention Type: DEVICE; Name: Impedance Threshold Device (ITD); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: Sham ITD; Assigned to Arm(s): 2 | Intervention Type: OTHER; Name: Analyze early; Assigned to Arm(s): 3 | Intervention Type: OTHER; Name: Analyze later; Assigned to Arm(s): 4
B: Arm Label: 1:Mechanical CPR with LUCAS; Type: EXPERIMENTAL; Interventions: Device: LUCAS | Arm Label: 2 Manual CPR; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional manual resuscitation method | Intervention Type: DEVICE; Name: LUCAS; Assigned to Arm(s): 1:Mechanical CPR with LUCAS | Intervention Type: OTHER; Name: Conventional manual resuscitation method; Assigned to Arm(s): 2 Manual CPR
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard cardiopulmonary resuscitation (S-CPR) | Intervention Type: DEVICE; Name: Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: Standard cardiopulmonary resuscitation (S-CPR); Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: AutoPulse | Arm Label: 2; Type: OTHER; Interventions: Other: Manual | Intervention Type: DEVICE; Name: AutoPulse; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Manual; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates
Brief Summary: We hypothesize that the success rate for keeping babies extubated (without a breathing tube for assisted mechanical ventilation), defined as the proportion of infants remaining extubated for a minimum of 72 hours, will be equivalent among infants managed with nasal CPAP compared to humidified high flow nasal cannula (HHFNC).


Options:
A: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A
B: Arm Label: Group 1; Type: OTHER; Interventions: Device: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen | Arm Label: Group 2; Type: OTHER; Interventions: Device: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen | Intervention Type: DEVICE; Name: High-Flow Nasal Oxygen / Non-invasive ventilation / Standard oxygen; Assigned to Arm(s): Group 1, Group 2
C: Arm Label: HHFNC; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Intervention Type: OTHER; Name: Nasal CPAP; Assigned to Arm(s): HHFNC, nCPAP | Intervention Type: OTHER; Name: Humidified High Flow Nasal Cannula (HHFNC); Assigned to Arm(s): HHFNC, nCPAP
D: Arm Label: High flows; Type: OTHER; Interventions: Device: Use of high flows versus oxygen therapy, Device: oxygen therapy | Arm Label: oxygen therapy; Type: OTHER; Interventions: Device: oxygen therapy | Intervention Type: DEVICE; Name: Use of high flows versus oxygen therapy; Assigned to Arm(s): High flows | Intervention Type: DEVICE; Name: oxygen therapy; Assigned to Arm(s): High flows, oxygen therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates
Brief Summary: We hypothesize that the success rate for keeping babies extubated (without a breathing tube for assisted mechanical ventilation), defined as the proportion of infants remaining extubated for a minimum of 72 hours, will be equivalent among infants managed with nasal CPAP compared to humidified high flow nasal cannula (HHFNC).


Options:
A: Arm Label: HFNC; Type: EXPERIMENTAL; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Intervention Type: DEVICE; Name: Respiratory support HFNC; Assigned to Arm(s): HFNC, nCPAP | Intervention Type: DEVICE; Name: Respiratory support NCPAP; Assigned to Arm(s): HFNC, nCPAP
B: Intervention Type: DEVICE; Name: High Flow Nasal Cannula; Assigned to Arm(s): N/A
C: Arm Label: HHFNC; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Intervention Type: OTHER; Name: Nasal CPAP; Assigned to Arm(s): HHFNC, nCPAP | Intervention Type: OTHER; Name: Humidified High Flow Nasal Cannula (HHFNC); Assigned to Arm(s): HHFNC, nCPAP
D: Arm Label: CPAP group; Type: EXPERIMENTAL; Interventions: Device: CPAP | Arm Label: Nasal Cannula Group; Type: EXPERIMENTAL; Interventions: Device: Nasal Cannula | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): CPAP group | Intervention Type: DEVICE; Name: Nasal Cannula; Assigned to Arm(s): Nasal Cannula Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparison of Humidified High Flow Nasal Cannula to Nasal Continuous Positive Airway Pressure for Non-Invasive Respiratory Support in Neonates
Brief Summary: We hypothesize that the success rate for keeping babies extubated (without a breathing tube for assisted mechanical ventilation), defined as the proportion of infants remaining extubated for a minimum of 72 hours, will be equivalent among infants managed with nasal CPAP compared to humidified high flow nasal cannula (HHFNC).


Options:
A: Arm Label: HHFNC; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Other: Nasal CPAP, Other: Humidified High Flow Nasal Cannula (HHFNC) | Intervention Type: OTHER; Name: Nasal CPAP; Assigned to Arm(s): HHFNC, nCPAP | Intervention Type: OTHER; Name: Humidified High Flow Nasal Cannula (HHFNC); Assigned to Arm(s): HHFNC, nCPAP
B: Arm Label: HFNC; Type: EXPERIMENTAL; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Arm Label: nCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: Respiratory support HFNC, Device: Respiratory support NCPAP | Intervention Type: DEVICE; Name: Respiratory support HFNC; Assigned to Arm(s): HFNC, nCPAP | Intervention Type: DEVICE; Name: Respiratory support NCPAP; Assigned to Arm(s): HFNC, nCPAP
C: Arm Label: NIMV- nasal respiratory support; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Arm Label: HFNC- nasal respiratory support with HFNC; Type: EXPERIMENTAL; Interventions: Device: NIMV with SLE ventilator vs HFNC via Vapotherm | Intervention Type: DEVICE; Name: NIMV with SLE ventilator vs HFNC via Vapotherm; Assigned to Arm(s): HFNC- nasal respiratory support with HFNC, NIMV- nasal respiratory support
D: Arm Label: HHHFNC; Type: EXPERIMENTAL; Interventions: Device: HHHFNC | Arm Label: NCPAP; Type: ACTIVE_COMPARATOR; Interventions: Device: NCPAP | Intervention Type: DEVICE; Name: HHHFNC; Assigned to Arm(s): HHHFNC | Intervention Type: DEVICE; Name: NCPAP; Assigned to Arm(s): NCPAP

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial
Brief Summary: The aim of this study is to investigate whether pharmacological pre-treatment with levosimendan reduces intensive care unit (ICU) length of stay in patients undergoing elective myocardial revascularization under cardiopulmonary bypass.


Options:
A: Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Intervention Type: PROCEDURE; Name: angioplasty, transluminal, percutaneous coronary; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: coronary artery bypass; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: thrombolytic therapy; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DEVICE; Name: Intra-aortic balloon pump counterpulsation; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Levosimendan Pre-Treatment in Patients Undergoing Coronary Artery Bypass Graft Surgery: a Double-Blind, Single Center, Prospective, Randomized, Placebo-Controlled Trial
Brief Summary: The aim of this study is to investigate whether pharmacological pre-treatment with levosimendan reduces intensive care unit (ICU) length of stay in patients undergoing elective myocardial revascularization under cardiopulmonary bypass.


Options:
A: Arm Label: L; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: P; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): L | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P
B: Arm Label: Levosimendan; Type: EXPERIMENTAL; Interventions: Drug: Levosimendan | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Levosimendan; Assigned to Arm(s): Levosimendan | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Normal saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Arm Label: Milrinone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milrinone | Intervention Type: DRUG; Name: Milrinone; Assigned to Arm(s): Milrinone | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Normal saline
D: Arm Label: levosimendan; Type: EXPERIMENTAL; Interventions: Drug: levosimendan | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: levosimendan; Assigned to Arm(s): levosimendan | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study, Tolerability, and Efficacy of Rilonacept for the Prevention of Gout Flares During Initiation of Allopurinol Therapy
Brief Summary: This was a clinical research study to determine the safety and effectiveness of an experimental drug called rilonacept in participants with gout who were beginning another additional treatment. Participants participated in this study for approximately 24 weeks. Rilonacept was being studied for use in preventing gout attacks in participants who had gout.


Options:
A: Arm Label: Febuxostat 40 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol 200 mg or 300 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 40 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol 200 mg or 300 mg QD
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo (for Rilonacept) | Arm Label: Rilonacept 160 mg; Type: EXPERIMENTAL; Interventions: Biological: Rilonacept | Intervention Type: BIOLOGICAL; Name: Rilonacept; Assigned to Arm(s): Rilonacept 160 mg | Intervention Type: OTHER; Name: Placebo (for Rilonacept); Assigned to Arm(s): Placebo
C: Arm Label: Allopurinol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Febuxostat 80 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 120 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Febuxostat 240 mg QD; Type: EXPERIMENTAL; Interventions: Drug: Febuxostat | Arm Label: Allopurinol QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: Allopurinol | Arm Label: Placebo QD; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 80 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 120 mg QD | Intervention Type: DRUG; Name: Febuxostat; Assigned to Arm(s): Febuxostat 240 mg QD | Intervention Type: DRUG; Name: Allopurinol; Assigned to Arm(s): Allopurinol QD | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo QD

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa
Brief Summary: The purpose of this study is to assess the clinical efficacy of azithromycin, used as a quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.


Options:
A: Arm Label: Azithromycin, 250 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Macrolide Antibiotic (Azithromycin) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Macrolide Antibiotic (Azithromycin); Assigned to Arm(s): Azithromycin, 250 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin and Placebo for Azithromycin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azithromycin | Arm Label: Placebo for Azithromycin; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo for Azithromycin | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin and Placebo for Azithromycin | Intervention Type: DRUG; Name: Placebo for Azithromycin; Assigned to Arm(s): Placebo for Azithromycin
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gentamicin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Saline | Intervention Type: DRUG; Name: Gentamicin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Saline; Assigned to Arm(s): 2
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Proof of Concept Study to Investigate the Impact of Azithromycin Administered iv Versus Placebo on the Prevention of Pneumonia in Ventilated Patients Colonized by Pseudomonas Aeruginosa
Brief Summary: The purpose of this study is to assess the clinical efficacy of azithromycin, used as a quorum-sensing blocker, when compared to placebo for preventing or delaying the occurrence of pneumonia in ventilated patients colonized with Pseudomonas aeruginosa.


Options:
A: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: erythromycin; Type: EXPERIMENTAL; Interventions: Drug: Erythromycin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Erythromycin; Assigned to Arm(s): erythromycin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: azithromycin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: azithromycin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Prevalence of Rickets and Subclinical Maternal and Childhood Vitamin D Deficiency in the Middle East: a Randomized Controlled Trial of Prenatal Vitamin D Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
Brief Summary: The purpose of this research study is to compare the effects of higher dose vitamin D with commonly recommended dose in pregnant women to see which is better in achieving and/or maintaining sufficient vitamin D blood levels during pregnancy and in newborn infants as well as improving growth in the infant.


Options:
A: Arm Label: Prenatal Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prenatal Vitamin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Intervention Type: DRUG; Name: Prenatal Vitamin; Assigned to Arm(s): 2, 3, Prenatal Vitamin D3 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 3
B: Arm Label: Vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Cholecalciferol D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo tablet | Intervention Type: DIETARY_SUPPLEMENT; Name: Cholecalciferol D3; Assigned to Arm(s): Vitamin D | Intervention Type: OTHER; Name: Placebo tablet; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
D: Arm Label: Regimen A; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Regimen A calcium and iron/folic acid | Arm Label: Regimen B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Regimen B calcium and iron/folic acid | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen A calcium and iron/folic acid; Assigned to Arm(s): Regimen A | Intervention Type: DIETARY_SUPPLEMENT; Name: Regimen B calcium and iron/folic acid; Assigned to Arm(s): Regimen B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: High Prevalence of Rickets and Subclinical Maternal and Childhood Vitamin D Deficiency in the Middle East: a Randomized Controlled Trial of Prenatal Vitamin D Supplementation to Prevent Vitamin D Deficiency in Mothers and Their Infants
Brief Summary: The purpose of this research study is to compare the effects of higher dose vitamin D with commonly recommended dose in pregnant women to see which is better in achieving and/or maintaining sufficient vitamin D blood levels during pregnancy and in newborn infants as well as improving growth in the infant.


Options:
A: Arm Label: 400 IU Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: 400 IU vitamin D3 | Arm Label: 2,000 IU Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 2,000 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 400 IU vitamin D3; Assigned to Arm(s): 400 IU Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 2,000 IU Vitamin D3; Assigned to Arm(s): 2,000 IU Vitamin D3
B: Arm Label: Prenatal Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prenatal Vitamin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Intervention Type: DRUG; Name: Prenatal Vitamin; Assigned to Arm(s): 2, 3, Prenatal Vitamin D3 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 3
C: Arm Label: A1 - non-pregnant single-dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: A2 - non-pregnant; weekly dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: B1 - pregnant; single-dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: B2 - pregnant; weekly dose; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: C1 - active control; pregnant women; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): A1 - non-pregnant single-dose, B1 - pregnant; single-dose | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): A2 - non-pregnant; weekly dose, B2 - pregnant; weekly dose | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): C1 - active control; pregnant women
D: Arm Label: Vitamin D treatment; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D 3 cholecalciferol, Dietary Supplement: Vitamin D3 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D 3 cholecalciferol; Assigned to Arm(s): Vitamin D treatment | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Vitamin D treatment, placebo

Answer: B